Research and Markets: Therapy Trends: Multiple Sclerosis

DUBLIN--()--Dublin - Research and Markets (http://www.researchandmarkets.com/research/2z54ns/therapy_trends_mu) has announced the addition of the "Therapy Trends: Multiple Sclerosis" report to their offering.

On the cusp of a treatment revolution

An incisive report and dynamic analyst briefing service delivering insight from the most influential Multiple Sclerosis (MS) Key Opinion Leaders to map the current treatment landscape and analyse future trends.

Multiple Sclerosis: On the cusp of a treatment revolution

The year 2012 will see landmark changes in the treatment of MS. Gilenya, the first novel drug in five years, is to be joined by three new products; BG-12 from Biogen Idec, Sanofi's Aubagio and Genzyme's Lemtrada. These drugs will partially satisfy substantial unmet needs of convenient administration and more efficacious therapy to drive unprecedented market growth.

Driven by in-depth interviews with the world's leading multiple sclerosis KOLs, Therapy Trends: Multiple Sclerosis uncovers how the current treatment landscape will be impacted by significant future events, with particular focus on pipeline therapies and how these will modify the way MS is managed by neurologists in the future.

Drive your strategic decision-making with inside intelligence

Therapy Trends: Multiple Sclerosis disseminates critical opinion and analysis to provide premier research.

- We cut to the heart of market-changing events and eliminate superfluous background information so you can focus on developments of greatest strategic impact and reduce your reaction time

- Our unique thought-leader selection matrix identifies the most influential KOLs in MS to deliver the perspectives vital in giving you a competitive edge, enabling informed decision-making and planning

- Detailed analysis of marketed and pipeline drugs helps you understand the products that will shape the future MS market

- KOL consensus on the future treatment algorithm offers a window into the future changes in medical evidence and clinical practice

- Uncovering KOLs' opinions on unmet needs enables you to identify potential commercial opportunities

- Dynamic report updates evaluate the market impact of key events from KOL perspectives, allowing you to react to significant MS market developments within days of events occurring

For more information visit http://www.researchandmarkets.com/research/2z54ns/therapy_trends_mu

Contacts

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): 353-1-481-1716
Sector: Central Nervous System

Contacts

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): 353-1-481-1716
Sector: Central Nervous System